Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

Launched by GLAUKOS CORPORATION · Jul 10, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new version of a small eye implant called the Travoprost Intracameral Implant to see if it is safe and effective for treating glaucoma, a condition that causes pressure build-up in the eye and can lead to vision loss. The implant is designed to help lower eye pressure over time by slowly releasing medication inside the eye.

Adults between the ages of 65 and 74 who have certain types of glaucoma or high eye pressure in one eye may be eligible to join. However, people who have had certain types of eye surgeries for glaucoma before are not eligible. If you participate, you can expect the implant to be placed inside your eye, and the study team will closely monitor your eye health to see how well the implant works and to check for any side effects. This study is currently looking for volunteers, so if you or a loved one fits the criteria, this might be an option to discuss with your eye doctor.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of open-angle glaucoma or ocular hypertension in the study eye
• Exclusion Criteria:
• • Prior incisional glaucoma surgery in the study eye
• • Prior argon laser trabeculoplasty (ALT) in the study eye
• • Prior minimally invasive glaucoma (MIGS) surgery in the study eye